Loading clinical trials...
Loading clinical trials...
The Effect of Selective Adrenal Artery Embolization and Spironolactone on Ventricular Remodeling in Nondominant Lateral Secretory Primary Aldosteronism： A Randomized Controlled Clinical Study
The study aims to assess the effect of superselective adrenal arterial embolization on ventricular remodeling in primary aldosteronism without lateralized aldosterone secretion by comparing it with spironolactone therapy.
After being informed about the study and potential risks,all patients giving written informedconsent will undergo a 2-week screening period to determine eligibility for study entry.Atweek 0,patients who meet the eligibility requirements will be randomized in a 1:1 ratio to Superselective adrenal arterial embolization group or spironolactone therapy group.
Age
18 - 60 years
Sex
ALL
Healthy Volunteers
No
The Second Affiliated Hospital of Nanchang University
Nanchang, China
Start Date
September 1, 2022
Primary Completion Date
September 1, 2025
Completion Date
December 31, 2025
Last Updated
May 16, 2025
112
ESTIMATED participants
Super selective adrenal artery embolization
OTHER
Spironolactone
DRUG
Lead Sponsor
Second Affiliated Hospital of Nanchang University
NCT05405101
NCT06833437
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07378176